Physician profile

Mikhail Romashko

Cardiovascular Disease · Biddeford, ME

NPI 1427407931

$1,421.46

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$66.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $255.54 2020-2022
Chiesi USA, INC. $202.67 2019-2022
Janssen Pharmaceuticals, INC $158.40 2019-2022
Astellas Pharma US INC $154.99 2020
Amgen INC. $154.84 2020-2022
Astrazeneca Pharmaceuticals Lp $146.80 2020-2022
Abbott Laboratories $135.46 2021
Ge Healthcare $66.68 2024
Daiichi Sankyo INC. $22.23 2022
Medtronic Vascular, INC. $22.06 2019
Pfizer INC. $21.79 2022
Bayer Healthcare Pharmaceuticals INC. $17.46 2022
Amarin Pharma, INC. $17.37 2019
Novo Nordisk INC $16.59 2021
Esperion Therapeutics, INC. $14.66 2021
Show all 16 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $13.92 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mikhail Romashko

$1,421.46

in general payments reported 2019-2025

Years
2019-2024
Top company
Zoll Services LLC (A/K/A Zoll Lifecor Corp)

https://glasscript.com/doctor/1674601/mikhail-romashko

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.